FEATURED NEWS
Prof. Glenwood Goss said adjuvant durvalumab did not improve disease-free survival outcomes following complete resection and optional chemotherapy. Read more
LATEST NEWS
Prof. Benjamin Besse said the TKI showed encouraging clinical activity in patients who were heavily pre-treated. Read more
Dr. Alexander Drilon said most patients with ALK-positive NSCLC treated with NVL-655 showed disease regression and deep responses. Read more
Dr. Matt Warkentin says in those without significant comorbidity and who are fit for surgery, screening may provide survival benefits. Read more